HSF1-IN-3
HSF1-IN-3 is a heat shock transcription factor 1 (HSF1) inhibitor with a Kd value of 23.8 μM against HSF1-DBD. HSF1-IN-3 inhibits the proliferation of cancer cells and induces their apoptosis, with stronger activity in androgen-dependent prostate cancer cells. HSF1-IN-3 reduces the expression of HSP70 and HSP90, downstream effectors of HSF1, and attenuates HSE-driven transcriptional activity. HSF1-IN-3 can be used in the research of cancers such as prostate cancer and leukemia.
For research use only. We do not sell to patients.
- Formula: C18H18BN3
- Molecular Weight:287.17
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
HSF1 23.8 μM (Kd) |
HSP70 |
HSP90 |
In Vitro
HSF1-IN-3 (Compound 1168) (0.78-25 μM; 30 min) dose-dependently disrupts the formation of purified recombinant human HSF1-DBD/HSE DNA complexes, with nearly complete inhibition observed at 12.5 μM[1].
HSF1-IN-3 (4-20 μM; 72 h) inhibits the proliferation of various cancer cell lines (HCT116, PC-3, LNCaP, 22Rv1, K562, A549, HL60, HeLa), with IC50 values ranging from 7.5 μM (HL60) to 19.5 μM (HeLa) after 72 h of treatment; meanwhile, the IC50 value of this compound in non-cancerous HEK293 cells is 4-fold higher, indicating a potential therapeutic window[1].
HSF1-IN-3 (2.5-20 μM; 10 days) inhibits the long-term clonogenic capacity of 22Rv1 prostate cancer cells in a dose-dependent manner[1].
HSF1-IN-3 (5-20 μM; 48 h) activates the caspase-dependent apoptotic signaling pathway in HL60 leukemia cells in a dose- and time-dependent manner[1].
HSF1-IN-3 (5-20 μM; 7-48 h) dose-dependently inhibits the expression of HSF1 and its downstream effector proteins (HSP70, HSP90, Akt) in HL60 leukemia cells and 22Rv1 prostate cancer cells under both basal and heat shock conditions. In addition, it reduces the level of androgen receptor in 22Rv1 cells[1].
HSF1-IN-3 (5-20 μM; 7 h) dose-dependently inhibits HSE-mediated transcriptional activity in HEK293T cells, with an inhibition rate of approximately 70% at the concentration of 20 μM after heat shock treatment[1].
HSF1-IN-3 (5-20 μM; 7 h) dose-dependently attenuates heat shock-induced phosphorylation of HSF1 Ser326 in 22Rv1 prostate cancer cells[1].
HSF1-IN-3 (5-20 μM; 7 h) dose-dependently attenuates heat shock-induced phosphorylation of HSF1 Ser326 in HL60 leukemia cells, and this effect is independent of its downregulatory action on total HSF1 protein levels[1].
HSF1-IN-3 (5-20 μM; 7 h) dose-dependently reduces the abundance of HSF1 trimers in heat shock-induced HL60 leukemia cells, and this effect is partially mediated by the proteasome-dependent degradation of HSF1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HL60 cells
-
Concentration:2.5, 5, 10 and 20 μM
-
Incubation Time:10 days
-
Result:Dose-dependently impaired the long-term clonogenic growth of 22Rv1 prostate cancer cells, with near-complete inhibition at 20 μM after 10 days.
-
Cell Line:HL60 cells
-
Concentration:5, 10 and 20 μM
-
Incubation Time:48 and 72 h
-
Result:Induced time-dependent apoptosis in HL60 leukemia cells, with 75.60% early apoptosis at 20 μM after 48 h and 83.39% late apoptosis at 20 μM after 72 h.
-
Cell Line:HL60 cells
-
Concentration:5, 10 and 20 μM
-
Incubation Time:Basal conditions for 48 h or under heat shock conditions (2 h pretreatment, 1 h at 43 ◦C, followed by 4 h
recovery) -
Result:Dose-dependently suppressed the expression of HSF1 and its downstream effector proteins (HSP70, HSP90, Akt) in HL60 leukemia cells and 22Rv1 prostate cancer cells under both basal and heat shock conditions, and additionally reduced androgen receptor levels.
Chemical Information
-
Molecular Weight 287.17
-
Formula C18H18BN3
-
SMILES
CN(C=CN1C)C1BC2=NC3=C(C=CC=C3)C4=C2C=CC=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Nuclear Protein Extraction (High-Salt/Hypotonic Fractionation)
The high-salt/hypotonic fractionation method for nuclear protein extraction is based on the differential solubility of cellular components. Cytoplasmic proteins are extracted first using a hypotonic buffer that causes cell swelling and membrane rupture, followed by centrifugation to separate the cytoplasmic supernatant from the nuclear pellet. The nuclear pellet is then subjected to high-salt extraction (e. g. , 0. 4 M (NH4)2SO4 or 1 M NaCl) to solubilize tightly bound nuclear matrix proteins, including transcription factors, histones, and structural proteins associated with chromatin and the nuclear scaffold. This approach allows for the isolation of both soluble cytoplasmic proteins and salt-resistant nuclear proteins while minimizing cross-contamination.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Dual Luciferin reporter gene assay
Luciferin reporter gene assay is a reporting system to detect the activity of Firefly Luciferase using luciferin as a substrate, which is often used in the research of miRNA target gene verification and promoter transcriptive activity regulation. Dual luciferase usually refers to Firefly luciferase and Renilla luciferase.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)